Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial
Open Access
- 12 November 2022
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 221, 157-163
Abstract
No abstract availableKeywords
Funding Information
- SNF
- UZH
- University Hospital Zurich
This publication has 27 references indexed in Scilit:
- The hypercoagulable state in COVID-19: Incidence, pathophysiology, and managementThrombosis Research, 2020
- Extrapulmonary manifestations of COVID-19: Radiologic and clinical overviewClinical Imaging, 2020
- COVID-19 is, in the end, an endothelial diseaseEuropean Heart Journal, 2020
- Extrapulmonary manifestations of COVID-19Nature Medicine, 2020
- Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysisThrombosis Research, 2020
- Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, ItalyThrombosis Research, 2020
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-UpJACC, 2020
- Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysisPLOS Medicine, 2019
- Low-Molecular-Weight Heparin and Mortality in Acutely Ill Medical PatientsNew England Journal of Medicine, 2011
- A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical PatientsNew England Journal of Medicine, 1999